Linked Life Data

19248973

Source:http://linkedlifedata.com/resource/pubmed/id/19248973

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-3-2
pubmed:abstractText
Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the targeted treatment of various cancers, including gastrointestinal stromal tumors (GISTs). Recent evidence suggests the possibility of cardiotoxicity secondary to TKI treatment of GISTs. Preclinical studies indicate that imatinib and sunitinib may be directly toxic to cardiac myocytes. Clinically, cardiotoxicity attributable to imatinib seems to be infrequent and manageable, whereas that attributable to sunitinib is more common and more severe. Further prospective studies with objective cardiac monitoring and long-term follow up are needed to define more accurately the incidence, natural history, and risk factors for developing cardiotoxicity associated with TKIs used in the treatment of patients who have GISTs. In this review, the authors discuss what is known regarding the cardiovascular effects of TKIs used in the treatment of GISTs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1558-1977
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
97-107, viii-ix
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.
pubmed:affiliation
Department of Cardiology, University of Texas, M.D. Anderson Cancer Center, Institute of Biosciences and Technology, Room 718, 2121 West Holcombe Boulevard, Houston, TX 77030, USA.
pubmed:publicationType
Journal Article, Review